Baxdrostat reduces SBP in uncontrolled and resistant hypertension: Results from the phase 3 BaxHTN trial

Predicted CVD risk reduction with tirzepatide vs. semaglutide in obesity: Insights from SURMOUNT-5

Refining risk stratification and treatment in dyslipidemia: The 2025 ESC/EAS focused update

Vericiguat improves survival and CV outcomes across broad HFrEF spectrum: Results from the VICTOR and VICTORIA pooled analysis

Inclisiran-based strategy improves LDL-C goal attainment and safety: Results from the phase 4 VICTORION-Difference trial